Testosterone raises IGF-1 on its own, so pairing it with sermorelin stacks two axes that interact rather than run in parallel. In older men, combined testosterone and growth hormone improved body composition and muscle performance beyond either therapy alone.
A sermorelin and testosterone stack pairs two different hormone therapies: testosterone replacement to restore androgen levels, and sermorelin to support the growth hormone axis that testosterone alone does not fully address. The two are not redundant. They act on separate systems that interact, and in older men a combined androgen-plus-GH intervention improved body composition and muscle performance beyond what either did alone [2]. The stack fits a specific man, and it depends entirely on monitoring.
- Testosterone and sermorelin act on different axes: TRT restores androgens, sermorelin supports the GH and IGF-1 axis [2]
- Testosterone administration raises IGF-1 on its own, so the two therapies interact rather than run in parallel [1]
- In older men, combined testosterone and GH improved body composition and muscle performance beyond either alone [2]
- The stack fits men on TRT who still have low or low-normal IGF-1 and residual body-composition or recovery complaints
- Monitoring is the whole game: baseline and follow-up testosterone, estradiol, hematocrit, PSA, and IGF-1
- Sermorelin is compounded, not FDA-approved, and both testosterone and GH secretagogues are prohibited in sport [7][8]
Why Combine Sermorelin With Testosterone
Testosterone replacement and sermorelin solve different problems. TRT corrects low testosterone: the libido, mood, and muscle complaints of male hypogonadism. It does not fully restore the growth hormone axis, which declines with age on its own timeline. Sermorelin targets that second axis by stimulating the pituitary to release the body's own GH, raising IGF-1 [5].
The two interact in a way that makes the pairing coherent. Testosterone itself raises IGF-1, so adding it to a GH-axis therapy is additive rather than parallel [1]. In a controlled trial of older men, testosterone combined with growth hormone improved lean mass, fat mass, and muscle performance more than either treatment produced alone [2]. The stack aims at the body-composition and recovery gap TRT by itself can leave.
Who the Stack Is For
This is a protocol for a specific man, not a default add-on for anyone on TRT. The candidate is a man already stabilized on testosterone replacement who still shows low or low-normal IGF-1 on a baseline draw, along with the symptoms the GH axis governs: poor sleep, slow recovery, stubborn visceral fat, or flat body-composition progress despite adequate testosterone.
- Men stabilized on TRT with low or low-normal IGF-1 on a baseline lab
- Residual complaints the GH axis governs: sleep, recovery, visceral fat, body composition
- Men willing to commit to the 6-month minimum and the monitoring the stack requires
- Not for men who have not first optimized testosterone, sleep, and training
- Not for men with active malignancy or a pituitary tumor
Testosterone comes first. A man whose low IGF-1 and fatigue are downstream of untreated low testosterone does not need a second peptide; he needs his TRT optimized. Sermorelin is added when the GH-axis symptoms persist after testosterone is in range, not stacked reflexively from day one.
How the Two Therapies Work Together
On the androgen side, testosterone replacement restores serum testosterone to a mid-normal range and, as a downstream effect, raises IGF-1 [1]. On the GH side, sermorelin stimulates pulsatile GH release at a starting dose of 100 to 300 mcg per day subcutaneously at bedtime, with IGF-1 rising over the first weeks and peaking around 90 days [5]. One therapy works through the androgen receptor, the other through the GH axis, and IGF-1 is the shared readout both move.
Two physiologic interactions are worth naming. Growth hormone lowers sex-hormone-binding globulin, which shifts the free-to-total testosterone ratio [6]. And transdermal testosterone altered GH pulsatility in older men with age-related low testosterone [4]. Both are reasons the two axes are monitored together rather than in isolation, because changing one can move the numbers on the other.
The Monitoring That Keeps It Safe
A sermorelin and testosterone stack is only as safe as its labs. Each therapy has its own monitoring, and the stack requires both panels, drawn at baseline and repeated on schedule. Skipping the baseline draw on either side is the red flag that separates a clinical protocol from a mail-order one.
| Marker | Why it is tracked | When |
|---|---|---|
| Total and free testosterone | Confirms TRT is in range, not over | Baseline, then periodically |
| Estradiol | Testosterone aromatizes; guides management | Baseline and follow-up |
| Hematocrit | TRT can raise red-cell mass | Baseline, then periodically |
| PSA | Prostate safety on TRT | Baseline and follow-up |
| IGF-1 | The GH-axis readout for sermorelin | Baseline and 90-day retest [5] |
The IGF-1 rule is the same one that governs any GH-axis therapy. Draw it before the first sermorelin dose, retest at about 90 days, and treat a result above the age-adjusted range as a reason to lower the dose rather than hold it [5]. On the testosterone side, hematocrit and PSA are the markers that decide whether TRT continues unchanged.
What to Expect and What Not To
The timeline is gradual on both axes. Testosterone effects on mood and libido appear over weeks; body-composition change from the combined protocol develops over a 6-month horizon alongside training and adequate protein [2]. Sermorelin does not produce a rapid visible change, because it resensitizes the pituitary rather than delivering hormone [5].
Two honest limits belong here. The strongest combined-therapy evidence used pharmaceutical growth hormone, not sermorelin, so applying its magnitude to a sermorelin stack is extrapolation [2]. And a growth hormone secretagogue raised IGF-1 in hypogonadal men without matching every downstream outcome men want from it [3]. The mechanism is sound; the size of the payoff for this specific pairing is not precisely measured.
Safety and Regulatory Standing
Sermorelin is dispensed as a compounded preparation, not an FDA-approved drug [7]. Testosterone replacement is FDA-approved and routinely prescribed, but it carries its own monitoring for hematocrit, estradiol, and prostate health. The combination should sit with a clinician who manages both, not two disconnected prescriptions.
For anyone subject to anti-doping testing, both halves are off the table. Testosterone and growth hormone secretagogues are prohibited in and out of competition under the 2026 WADA code [8]. That is decisive for competitive athletes and irrelevant to most men, but it belongs in the decision.
The Honest Verdict
A sermorelin and testosterone stack is a reasonable protocol for a defined man: one already stabilized on TRT whose IGF-1 and GH-axis symptoms still lag. The rationale is sound, because testosterone and the GH axis interact, and combined androgen-plus-GH therapy outperformed either alone in older men [2]. The catch is that the strongest evidence used pharmaceutical GH, and this stack has not been measured at that precision.
If it fits, the discipline is what makes it work. Optimize testosterone first. Draw a full baseline, testosterone, estradiol, hematocrit, PSA, and IGF-1, before adding sermorelin. Retest IGF-1 at 90 days and treat an above-range result as a reason to reduce the dose. Run it with a clinician who manages both axes, because the stack is a monitoring commitment, not a shortcut.
Sermorelin plus testosterone means two hormone axes and two monitoring panels, which is more than a single-prescription program is built for. PeterMD prescribes sermorelin and testosterone therapy on one platform with a physician evaluation and follow-up labs, so a combined protocol is monitored together rather than sourced from two places.
Frequently Asked Questions
Can you take sermorelin and testosterone together?
Yes, and the two are often managed together because they act on different axes that interact. Testosterone replacement restores androgens, sermorelin supports the GH and IGF-1 axis, and testosterone itself raises IGF-1, so the pairing is additive rather than redundant [1]. It should run under a clinician who monitors both, since changing one axis can move the numbers on the other.
What does adding sermorelin to TRT actually do?
It targets the growth hormone axis that testosterone alone does not fully restore. Sermorelin stimulates the pituitary to release GH, raising IGF-1 [5], which supports the sleep, recovery, and body-composition changes some men still lack on TRT. In older men, combined androgen and GH therapy improved body composition and muscle performance beyond either alone [2], though that study used pharmaceutical GH rather than sermorelin.
Who is a good candidate for a sermorelin and testosterone stack?
A man already stabilized on TRT who still shows low or low-normal IGF-1 on a baseline lab, along with GH-axis symptoms like poor sleep, slow recovery, or stubborn visceral fat. It is not a day-one default. If low testosterone is the real cause of the fatigue, optimizing TRT comes first, and sermorelin is added only if the GH-axis symptoms persist.
What labs do you need for a sermorelin and testosterone stack?
Both panels, at baseline and on follow-up: total and free testosterone, estradiol, hematocrit, and PSA on the TRT side, and IGF-1 on the sermorelin side [5]. IGF-1 is drawn before the first dose and retested at about 90 days, with an above-range result a reason to lower the dose. Hematocrit and PSA are what decide whether TRT continues unchanged.
Does testosterone raise IGF-1 on its own?
Yes. Testosterone administration increased IGF-1 in normal men [1], which is part of why it interacts with a GH-axis therapy rather than running parallel to it. It is also why IGF-1 is monitored when the two are stacked: the testosterone side moves the same marker sermorelin is dosed against.
Is a sermorelin and testosterone stack safe?
It is safe under monitoring and unsafe without it. Testosterone requires tracking of hematocrit, estradiol, and PSA, and sermorelin requires a baseline and 90-day IGF-1 [5]. Sermorelin is compounded, not FDA-approved [7], and both testosterone and GH secretagogues are prohibited in sport [8]. The combination belongs with a clinician who manages both axes.
References
- Testosterone administration increases insulin-like growth factor-I levels in normal men Journal of Clinical Endocrinology & Metabolism, 1993. PMID: 7690364. https://pubmed.ncbi.nlm.nih.gov/7690364/
- Testosterone and growth hormone improve body composition and muscle performance in older men Journal of Clinical Endocrinology & Metabolism, 2009. PMID: 19293261. https://pubmed.ncbi.nlm.nih.gov/19293261/
- Growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels American Journal of Men's Health, 2017. PMID: 28830317. https://pubmed.ncbi.nlm.nih.gov/28830317/
- Effects of transdermal testosterone gel or an aromatase inhibitor on serum concentration and pulsatility of growth hormone in older men with age-related low testosterone Metabolism, 2017. PMID: 28285644. https://pubmed.ncbi.nlm.nih.gov/28285644/
- Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women Journal of Clinical Endocrinology & Metabolism, 1997. PMID: 9141536. https://pubmed.ncbi.nlm.nih.gov/9141536/
- Continuous subcutaneous infusion of low dose growth hormone decreases serum sex-hormone binding globulin and testosterone concentrations in moderately obese middle-aged men Clinical Endocrinology (Oxford), 1996. PMID: 8706289. https://pubmed.ncbi.nlm.nih.gov/8706289/
- Certain bulk drug substances for use in compounding that may present significant safety risks FDA.gov, Human Drug Compounding, 2026. Content current as of 04/22/2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
